Dynamics of Cognitive Impairments in Patients with Parkinson’s Disease Receiving L-DOPA Treatment

Dynamics of Cognitive Impairments in Patients with Parkinson’s Disease Receiving L-DOPA Treatment

Objectives. To assess the dynamics of cognitive impairment (CI) in patients with Parkinson’s disease (PD) during L-DOPA treatment. Materials and methods. A randomized clinical trial included 41 patients with confirmed diagnoses of PD at stage 2.5–3.5 on the Hoehn and Yahr scale, mainly of the akinet...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience and behavioral physiology Vol. 52; no. 3; pp. 368 - 372
Main Authors: Ismailova, S. B., Prokopenko, S. V., Pokhabov, D. V., Mosaleva, E. I., Alekseenko, P. V., Zhumzhanov, I. M.
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 01-03-2022
Springer Nature B.V
Subjects:
Behavioral Sciences
Biomedical and Life Sciences
Biomedicine
Cognitive ability
Levodopa
Movement disorders
Neurobiology
Neurodegenerative diseases
Neurosciences
Parkinson's disease
Patients
Scopa
Statistical analysis
MoCA
neuropsychological investigations
levodopa
FAB
SCOPA-Cog
nonmotor manifestations
L-DOPA therapy
Parkinson’s disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. To assess the dynamics of cognitive impairment (CI) in patients with Parkinson’s disease (PD) during L-DOPA treatment. Materials and methods. A randomized clinical trial included 41 patients with confirmed diagnoses of PD at stage 2.5–3.5 on the Hoehn and Yahr scale, mainly of the akinetic-rigid and mixed forms, who were taking levodopa and had PD-associated CI syndrome. Mean duration of illness was five years. The design included randomization of study participants to two groups. The dynamics of CI were assessed using neuropsychological investigations on two occasions separated by six months: group 1 in the on and off phases of L-DOPA therapy and group 2 in the off and on phases of levodopa therapy, respectively. The state of CI was assessed on the Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment Scale (MoCA), the Frontal Assessment Battery (FAB), the Scales for Outcomes in Parkinson’s Disease – Cognition (SCOPA-Cog), and the Geriatric Depression Scale (GDS). Results. A statistically significant improvement in cognitive status was seen at the on phase of levodopa action, along with degradation in the off phase of L-DOPA therapy in the form of increased cognitive deficit ( p < 0.05). Conclusions. CI in PD may to some extent be dependent on L-DOPA therapy, as well as on motor signs. The most dynamic functions on the background of L-DOPA therapy were attention, language, and executive and visuospatial functions.
ISSN:0097-0549
1573-899X
DOI:10.1007/s11055-022-01250-2